Retension Pharmaceuticals: Sweetnam converts 4,026 shares

Both preferred-stock classes converted automatically into common shares immediately before the IPO closing, without payment of consideration.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Retension Pharmaceuticals, Inc. (RTSN) Chief Scientific Officer Paul Sweetnam converted 4,026 Series A Convertible Preferred Stock shares into 4,026 common shares on October 13, 2026. The Series A shares converted automatically immediately before the initial public offering closed, without payment of consideration. His spouse’s 2,640 Series B Convertible Preferred Stock shares also converted automatically into 2,640 common shares without payment of consideration. Afterward, Paul Sweetnam directly held 406,603 common shares, and his spouse indirectly held 2,640 common shares.

Insider Trade Summary

6,666 shares exercised/converted

Exercise 4 txns

Insider Sweetnam Paul

Role CHIEF SCIENTIFIC OFFICER

Type	Security	Shares	Price	Value
Conversion	Series A Convertible Preferred Stock ^F1	4,026	--	--
Conversion	Series B Convertible Preferred Stock ^F2	2,640	--	--
Conversion	Common Stock ^F1	4,026	--	--
Conversion	Common Stock ^F2	2,640	--	--

Holdings After Transaction: Series A Convertible Preferred Stock — 0 contracts (Direct); Series B Convertible Preferred Stock — 0 contracts (Indirect, By Spouse); Common Stock — 406,603 shares (Direct); Common Stock — 2,640 shares (Indirect, By Spouse)

Footnotes (2)

F1. Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had no expiration date.
F2. Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date.

Key Figures

Series A Convertible Preferred Stock converted: 4,026 shares Common shares acquired through Series A conversion: 4,026 shares Series B Convertible Preferred Stock converted: 2,640 shares +3 more

6 metrics

Series A Convertible Preferred Stock converted 4,026 shares October 13, 2026

Common shares acquired through Series A conversion 4,026 shares October 13, 2026

Series B Convertible Preferred Stock converted 2,640 shares Held by Paul Sweetnam’s spouse; October 13, 2026

Common shares acquired through Series B conversion 2,640 shares Held indirectly by Paul Sweetnam’s spouse; October 13, 2026

Paul Sweetnam direct common shares after transaction 406,603 shares After the October 13, 2026 transaction

Spouse’s indirect common shares after transaction 2,640 shares After the October 13, 2026 transaction

Key Terms

Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, initial public offering, without payment of consideration

4 terms

Series A Convertible Preferred Stock financial

"Each share of Series A Convertible Preferred Stock"

Series A convertible preferred stock is a class of shares sold in an early funding round that gives investors a mix of protection and upside: it pays a priority claim over common shares if the company is sold or closes, but can be converted into ordinary shares to share in future growth. Think of it like a hybrid between a safer stake and a ticket to ownership; it matters to investors because it affects who controls the company, how future gains are split, and how much their investment is protected from downside.

Series B Convertible Preferred Stock financial

"Each share of Series B Convertible Preferred Stock"

Series B convertible preferred stock is a class of shares sold during a later-stage private financing that combines features of a loan and common stock: it usually pays priority dividends or has a priority claim if the company is sold, and it can be converted into common shares under predefined rules. Investors care because these shares affect ownership stakes and payout order—like having a reserved place in line and a ticket that can turn into regular ownership—so they influence potential returns and dilution for other shareholders.

initial public offering financial

"prior to the closing of the Issuer's initial public offering"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

without payment of consideration financial

"converted automatically into one share of Common Stock without payment of consideration"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many preferred shares were converted in the RTSN Form 4?

On October 13, 2026, Paul Sweetnam, Retension Pharmaceuticals’ chief scientific officer, converted 4,026 Series A preferred shares, and 2,640 Series B preferred shares held by his spouse converted. Each share converted automatically into one common share immediately before the initial public offering closed, without payment of consideration.

How many RTSN common shares did Paul Sweetnam and his spouse hold after the conversions?

After the October 13, 2026 conversions, Paul Sweetnam directly held 406,603 common shares, while his spouse indirectly held 2,640 common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/13/2026 - 08:14 PM EDT Accepted by SEC EDGAR 10/13/2026 - 06:12 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sweetnam Paul

(Last)

(First)

(Middle)

1104 WEST BROAD STREET

SUITE 1029

(Street)

FALLS CHURCH

VIRGINIA

22046

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Retension Pharmaceuticals, Inc. [ RTSN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF SCIENTIFIC OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/13/2026		C		4,026	A	⁽¹⁾	406,603	D
Common Stock	10/13/2026		C		2,640	A	⁽²⁾	2,640	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Series A Convertible Preferred Stock	⁽¹⁾	10/13/2026		C			4,026	⁽¹⁾	⁽¹⁾	Common Stock	4,026	⁽¹⁾	0	D
Series B Convertible Preferred Stock	⁽²⁾	10/13/2026		C			2,640	⁽²⁾	⁽²⁾	Common Stock	2,640	⁽²⁾	0	I	By Spouse

Explanation of Responses:

1. Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had no expiration date.

2. Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date.

	/s/ Alex Schwartz, Attorney-in-fact	10/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR